Testing Optical Genome Mapping in Ph-Negative Myeloproliferative Neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates Optical Genome Mapping (OGM) as a high-resolution method to identify structural and copy-number variations across the genome in Ph-negative myeloproliferative neoplasms. Eligible participants are adults with polycythemia vera, essential thrombocythemia, or myelofibrosis who require bone marrow cytogenetics. A peripheral blood or bone marrow sample will be analyzed using OGM to determine its sensitivity and potential to replace or supplement standard cytogenetic methods. The study aims to improve prognostic stratification by detecting abnormalities that may be missed by conventional techniques. Results will inform whether OGM can be integrated into routine cytogenetic characterization of hematologic malignancies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient 18 years of age or older
* Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis
* Requires bone marrow cytogenetics at diagnosis or follow-up
* Understanding of the French language
* Information of the patient and collection of no objection
* Person affiliated to a social security regime

Exclusion Criteria:

* Patient with BCR::ABL positive myeloproliferative neoplasia.
* Person with a medical history that may impair the ability to understand the information notice

Where it's running

• Centre Hospitalier Universitaire d'Amiens
  Amiens, Picardie, France Recruiting

Study contacts

• Study coordinator: Valentin Lestringant, MD
• Email: Lestringant.valentin@chu-amiens.fr
• Phone: 03 22 08 70 23

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Optical genome mapping to find genetic causes of congenital orofacial clefts

  This will test whether optical genome mapping on a blood sample can find structural genetic changes in people with syndromic, complex, or familial orofacial clefts who do not yet have a genetic diagnosis.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT06880094

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.